2-(氨基氧基)乙胺 | 4747-18-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(氨基氧基)乙胺
• 英文名称: O-(2-aminoethyl)hydroxylamine
• 英文别名: 1-aminooxy-2-aminoethane；(2-Amino-aethyloxy)amin；2-aminoethoxyamine；1-aminooxyethylamine；2-(Aminooxy)ethanamine
• CAS: 4747-18-6
• 化学式: C₂H₈N₂O
• mdl: MFCD19216296
• 分子量: 76.0983
• InChiKey: MECRKILGNPUEFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  5
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(氨基氧基)乙胺 、 (1S,3aS,5S,7aR)-3a-hydroxy-5-phenyl-7a-methylperhydroindene-1-carboxaldehyde 在 盐酸 、 sodium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以11%的产率得到(1S,3AS,5S,7AR)-1-[(E)-2-aminoethoxyimino]methyl-5-phenyl-7a-methylperhydroinden-3a-ol
  参考文献：
  名称：

  Synthesis and Inotropic Activity of 1-(O-Aminoalkyloximes) of Perhydroindene Derivatives as Simplified Digitalis-like Compounds Acting on the Na⁺,K⁺-ATPase

  摘要：

  A series of 5-substituted (3aS,7aR)-7a-methylperhydroinden-3a-ol derivatives bearing a 1(S)(omega-aminoalkoxy)iminoalkyl or -alkenyl substituent was synthesized, starting from the Hajos-Parrish ketol 47, as simplified analogues of very potent 17beta-aminoalkyloximes with digitalis skeleton, previously reported. The target compounds were evaluated in vitro for displacement of the specific [H-3]ouabain binding from the dog kidney Na+,K+-ATPase receptor. Some of them revealed IC50 values in the micromolar range. The most active compounds possess a cyclohexyl group in the 5(S) position and in position 1(S) the same aminoalkyloxime groups already reported for the digitoxigenin-like series in position 17beta. Although the ring conformation of these derivatives was comparable to that of uzarigenin, the binding affinities of the most active ones were 4/8-fold lower in comparison to that standard, Three compounds among those with the highest affinities were assayed in vitro for their inotropic activity on an electrically driven guinea pig left atrium and were found to be less potent than both digoxin, the most widely used inotropic agent, and the corresponding digitalis 17beta-aminoalkyloximes.

  DOI：

  10.1021/jm011001k
• 作为产物：
  描述：

  (乙烯氧基)二-氨基甲酸二乙酯 在 barium dihydroxide 作用下， 生成 2-(氨基氧基)乙胺
  参考文献：
  名称：

  BACTERIOSTATS: III. OXYAMINES AND THEIR DERIVATIVES

  摘要：

  为合成脲和硫脲衍生物，制备了一系列苄氧胺。苄氧胺盐酸盐与光气处理后生成相应的苄基4-(苄氧基)-异尿酸酯和苄氧基氨基甲酰氯的混合物。三乙胺将苄氧基氨基甲酰氯转化为相应的1,3,5-三-(苄氧基)-异氰酸酸。描述了异尿酸酯与胺和氢氧化钠的反应。

  DOI：

  10.1139/v60-050

文献信息

• NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME
  申请人：Cho Young Lag

  公开号：US20140179691A1

  公开（公告）日：2014-06-26

  Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.

  上述公开了一种新型噁唑烷酮衍生物，具体来说，是一种具有环氧胺肟基或环氧胺酮基团的新型噁唑烷酮化合物。 在公式1中，R和Q的定义与详细描述中的相同。 此外，公开了一种抗生素药物组合物，包括公式1中的新型噁唑烷酮衍生物，其前药，水合物，溶剂合物，异构体或其药学上可接受的盐作为活性成分。 该新型噁唑烷酮衍生物，其前药，水合物，溶剂合物，异构体和其药学上可接受的盐对耐药细菌具有广泛的抗菌谱，毒性低，并对革兰氏阳性和阴性细菌具有强效的抗菌作用，因此可以有效地用作抗生素。
• EP2692727
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis of 5,6-dihydro-4<i>H</i> -benzo[<i>d</i> ]isoxazol-7-one and 5,6-dihydro-4<i>H</i> -isoxazolo[5,4-<i>c</i> ]pyridin-7-one Derivatives as Potential Hsp90 Inhibitors
  作者：Loana Musso、Raffaella Cincinelli、Giuseppe Giannini、Fabrizio Manetti、Sabrina Dallavalle

  DOI：10.1111/cbdd.12570

  日期：2015.11

  A novel class of 5,6‐dihydro‐4H‐benzo[d]isoxazol‐7‐ones and 5,6‐dihydro‐4H‐isoxazolo[5,4‐c]pyridin‐7‐ones was designed, synthesized, and assayed to investigate the affinity toward Hsp90 protein. The synthetic route was based on a 1,3‐dipolar cycloaddition of nitriloxides, generated in situ from suitable benzaldoximes, with 2‐bromocyclohex‐2‐enones or 3‐bromo‐5,6‐dihydro‐1H‐pyridin‐2‐ones. Whereas all the compounds bearing a benzamide group on the bicyclic scaffold were devoid of activity, the derivatives carrying a resorcinol‐like fragment showed a remarkable inhibitory effect on Hsp90. Docking calculations were performed to investigate the orientation of the new compounds within the binding site of the enzyme.
• Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent
  作者：Yoshiaki Isshiki、Yasunori Kohchi、Hitoshi Iikura、Yasuaki Matsubara、Kohsuke Asoh、Takeshi Murata、Masami Kohchi、Eisaku Mizuguchi、Shinji Tsujii、Kazuo Hattori、Takaaki Miura、Yasushi Yoshimura、Satoshi Aida、Masanori Miwa、Ryoichi Saitoh、Naoaki Murao、Hisafumi Okabe、Charles Belunis、Cheryl Janson、Christine Lukacs、Verena Schück、Nobuo Shimma

  DOI：10.1016/j.bmcl.2011.01.062

  日期：2011.3

  The MAP kinase pathway is one of the most important pathways involved in cell proliferation and differentiation, and its components are promising targets for antitumor drugs. Design and synthesis of a novel MEK inhibitor, based on the 3D-structural information of the target enzyme, and then multidimensional optimization including metabolic stability, physicochemical properties and safety profiles were effectively performed and led to the identification of a clinical candidate for an orally available potent MEK inhibitor, CH4987655, possessing a unique 3-oxo-oxazinane ring structure at the 5-position of the benzamide core structure. CH4987655 exhibits slow dissociation from the MEK enzyme, remarkable in vivo antitumor efficacy both in mono-and combination therapy, desirable metabolic stability, and insignificant MEK inhibition in mouse brain, implying few CNS-related side effects in human. An excellent PK profile and clear target inhibition in PBMC were demonstrated in a healthy volunteer clinical study. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] SIALIC-ACID LIGAND DECORATED THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES DÉCORÉS PAR UN LIGAND D'ACIDE SIALIQUE
  申请人：AVICEDA THERAPEUTICS INC

  公开号：WO2022060984A8

  公开（公告）日：2023-04-27